(Firivumab)Biosimilar Reference Antibody-GS40270

货号：GS40270

Firivumab (development code VIS-410) is an investigational, human monoclonal antibody developed for the prevention and treatment of influenza A virus infection. It functions as a broadly neutralizing antibody targeting a conserved region on the influenza virus. By binding with high affinity to a specific epitope on the hemagglutinin (HA) surface glycoprotein of influenza A viruses, firivumab blocks a critical step in the viral life cycle. This neutralization prevents the virus from attaching to and entering host cells, thereby inhibiting infection. It is designed to be effective against a wide range of seasonal and potentially pandemic influenza A strains, including those resistant to standard antiviral neuraminidase inhibitors.